Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Drop in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 50,600 shares, a decrease of 29.8% from the February 13th total of 72,100 shares. Currently, 1.8% of the company’s shares are sold short. Based on an average trading volume of 42,500 shares, the short-interest ratio is currently 1.2 days.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently raised its position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC grew its holdings in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned approximately 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent filing with the SEC. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Stock Performance

KPRX stock traded up $0.04 during trading on Tuesday, hitting $3.33. The company had a trading volume of 586 shares, compared to its average volume of 32,921. The business has a 50-day moving average of $3.54 and a 200-day moving average of $3.50. Kiora Pharmaceuticals has a one year low of $2.91 and a one year high of $6.48.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.